## MAP4K2 inhibitor (TL4-12)

 $\begin{array}{c} \text{Chemical Formula: } C_{50} H_{54} F_6 N_{12} O_4 \\ \text{Molecular Weight: } 1001.05 \end{array}$ 

Category	Parameter	Description
Compound	Name	MAP4K2 inhibitor (TL4-12)
	Citation	J Med Chem. <b>2014</b> jm500480k.
	Chemical descriptors	CC1=CC=C(C(NC2=CC(N3CCN(C)CC3)=CC(C(F)(F)F)=C2)=O)C=C1OC4=NC=NC(NC)=C4
	Chemical name	4-methyl-3-((6-(methylamino)pyrimidin-4-yl)oxy)-N-(3-(4-methylpiperazin-1-yl)-5-(trifluoromethyl)phenyl)benzamide
	Availability	
In vitro profiling	Target (potency)	<b>MAP4K2</b> (37 nM IC50 in Z'-Lyte assay, 85% inhibition at 1.0 $\mu$ M IC50 in ActivX KiNativ assay)
	Additional Target (potency)	
	Selectivity	
	Potential reactivity	None to our knowledge
	SAR	
	Mechanism of inhibition	ATP-competitive
	Structure of target-probe complex	
Cellular profiling	Validation of cellular target	TL4-12 dose-dependently inhibited MAP4K2 downstream signaling induced by TGF $\beta$ in TAK1-null MEF cells with IC50 between 0.1~0.5 $\mu$ M.
		Compound phenotypes were compared to literature. The cellular effects were correlated with <i>in vitro</i> biochemical activities.
	Validation of cellular specificity	
Pharmacodynamics		
Pharmacokinetics		

Reagents and conditions: (a) 3-hydroxy-4-methylbenzoic acid, NaOH, acetone/H<sub>2</sub>O; (b) **4**, HATU, DMAP, DIEA, CH<sub>2</sub>Cl<sub>2</sub>; (c) methylamine, THF.